The Christie charity
Name
Ahmed Salem
Job title
Clinical Senior Lecturer in Lung Cancer Research and Honorary Clinical Oncology Consultant
Email Address
natalie.boyd@christie.nhs.uk
Phone number
0161 446 3337
Fax number
0161 446 8142
Qualifications
MB ChB, PGCert, MSc, PhD, FHEA, FESTRO, FRCR
Specialities
Thoracic malignancies
Started at The Christie (Year)
2014
Professional biography
Dr. Salem is a Senior Clinical Lecturer in Lung Cancer Research at the University of Manchester and an Honorary Consultant in Clinical Oncology at The Christie NHS Foundation Trust.
Clinically specializing in lung cancer radiotherapy, Dr. Salem’s research focuses on validating novel biomarkers of hypoxia and radiosensitivity in lung cancer patients, leading to the conduct of biomarker-driven clinical trials.
Dr. Salem has completed training in radiation oncology at King Hussein Cancer Centre (Amman, Jordan) in 2014, attaining fellowships & specialty certifications in clinical (FRCR), radiation (ESTRO fellowship & Jordanian board) and medical oncology (MRCP medical oncology & ESMO certification). He has also completed a clinical research fellowship in 2017, attaining a PhD in Medicine from the University of Manchester for research focusing on non-invasive therapeutic lung cancer biomarkers.
Dr. Salem has published more than 36 peer-reviewed papers and many abstracts, posters and proceedings in eminent oncology conferences. Dr. Salem is a recipient of more than 10 prestigious academic oncology awards such as the ESTRO Accuray Award and the ASTRO International-US annual meeting scientific abstract award.
Apart from research, Dr. Salem is a keen educationalist. He is a committee member in the Royal College of Radiologists clinical oncology professional learning and development subcommittee and serves as a co-chair of the ESTRO FALCON workshop operational group.
Dr. Salem’s career goal is to lead an innovative lung cancer radiotherapy research portfolio, aiming to deliver hypoxia-targeted therapies (with companion biomarkers) in the clinic by the next 15 years.